Question: Should new targeted molecular agents be used as neoadjuvant therapy for metastatic renal cell carcinoma?

Tannir, Nizar; Pili, Robertor
April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p11
The article provides two opposing answers to a question of whether targeted molecular agents should be used as neoadjuvant therapy for metastatic renal cell carcinoma.


Related Articles

  • Metastasizing Renal Cell Carcinoma Developing in a Congenital Ectopic and Dysplastic Kidney. Akkad, Thomas; Sergi, Consolato; Gozzi, Christian; Steiner, Hannes; Leonhartsberger, Nicolai; Mitterberger, Michael; Bartsch, Georg; Radmayr, Christian; Oswald, Josef // Urologia Internationalis;Nov2008, Vol. 81 Issue 4, p477 

    We present the first case of a metastasizing renal cell carcinoma arising within a partially regressed multicystic dysplastic and ectopic left kidney in a 34-year-old patient. Despite nephrectomy and adjuvant immunotherapy, the patient died 4 months after diagnosis. Even though a recent...

  • Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Verzoni, Elena; Grassi, Paolo; Testa, Isabella; Iacovelli, Roberto; Biondani, Pamela; Garanzini, Enrico; De Braud, Filippo; Procopio, Giuseppe // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p107 

    Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal...

  • The gene for von Hippel-Landau disease. Maher, Eamonn R. // BMJ: British Medical Journal (International Edition);7/31/93, Vol. 307 Issue 6899, p279 

    Examines the gene for von Hippel-Lindau disease in England. Characteristics of von Hippel-Lindau disease; Advantages of the direct molecular genetic diagnosis of von Hippel-Landau disease; Pathogenesis of renal cell carcinoma.

  • VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. Yao, Masahiro; Yoshida, Minoru; Kishida, Takeshi; Nakaigawa, Noboru; Baba, Masaya; Kobayashi, Kazuki; Miura, Takeshi; Moriyama, Masatoshi; Nagashima, Yoji; Nakatomi, Yukio; Kubota, Yoshinobu; Kondo, Kei-ichi; Nakatani, Yukio // JNCI: Journal of the National Cancer Institute;10/16/2002, Vol. 94 Issue 20, p1569 

    Background: Somatic alteration of the von Hippel-Lindau disease tumor suppressor gene (VHL) is one of the most common genetic changes observed in the sporadic, clear-cell subtype of renal cell carcinoma (RCC). However, the prognostic utility of VHL mutations has not been examined....

  • Tumor-induced factors may alter T-cell function in RCC. Schneider, Ellen Meyer // Urology Times;Jul99, Vol. 27 Issue 7, p11 

    Reports on the results of a study showing that growth of antigenic tumors proceeds in the absence of significant T-cell destruction in patients with renal cell carcinoma (RCC). Reasons for the alterations in T-cell signaling in patients with RCC; Mechanisms responsible for the alteration of...

  • Expression of apoptotic regulatory molecules in renal cell carcinoma: Elevated expression of Fas ligand. Olive, Colleen; Cheung, Catherine; Nicol, David; Falk, Michael C; Olive // Immunology & Cell Biology;Feb1999, Vol. 77 Issue 1, p11 

    Renal cell carcinoma (RCC) is the most common renal neoplasm. Despite being infiltrated by tumour infiltrating lymphocytes (TIL), these TIL are unable to control tumour growth in vivo, suggesting that the cytotoxic capacity of TIL against RCC is impaired, or that the tumour cells are resistant...

  • Interphase cytogenetics of multicentric renal cell tumours confirm associations of specific aberrations with defined cytomorphologies. Amo-Takyi, B K; Mittermayer, C; G√ľnther, K; Handt, S // British Journal of Cancer;4/15/2000, Vol. 82 Issue 8, p1407 

    To demonstrate associations of certain chromosomal aberrations with defined renal cell tumour (RCT) subtypes, we analysed 239 tumour nephrectomy cases for specimens with multicentric tumours. Chromosomal in situ hybridization was then performed on 15 cases with 34 foci (16 conventional renal...

  • Erratum.  // JNCI: Journal of the National Cancer Institute;Apr2012, Vol. 104 Issue 8, p638 

    A correction to the article "Targeted Therapies for Renal Cell Carcinoma (RCC): Review of Adverse Event Management Strategies," by Eisen and colleagues, published in previous issue is presented.

  • Management of renal cell cancer. Droller, Michael J. // Cortlandt Forum;2/25/96, Vol. 9 Issue 2, p190 

    Presents a question and answer advisory for managing renal cell cancer. Symptoms; Diagnostic tests; Implications of kidney mass; Kidney cancer prevention.

  • Axitinib, Sorafenib Offer Similar Survival, Data Show. SCHIESZER, JOHN // Renal & Urology News;Nov2012, Vol. 11 Issue 11, p21 

    The article presents information on the findings of a study according to which axitinib therapy is associated with overall survival (OS) like that of sorafenib therapy as second-line treatment of metastatic renal cell carcinoma (mRCC).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics